相关实验视频

Updated: Apr 13, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

在腹膜透析中,empagliflozin通过衰老减弱了表皮细胞到介质细胞的过渡

Yunmee Lho^1,2, Yeong Park^1,2, Jun Young Do²

¹Senotherpy-Based Metabolic Disease Control Research Center, College of Medicine, Yeungnam University, Daegu, Republic of Korea.

American journal of physiology. Renal physiology

|July 4, 2024

概括

作为SGLT2抑制剂的empagliflozin通过降低衰老来降低表皮细胞到介质细胞的过渡 (EMT). 这项研究表明,empagliflozin在腹腔透析模型中减弱了EMT和纤维化,表明其作为一种新疗法战略的潜力.

科学领域:

细胞生物学细胞生物学
腎臟病學 (nephrology) 是一種醫學專業.
药理学药理学是指药理学的学科.

背景情况:

皮质到介质细胞的过渡 (EMT) 与衰老有关,并有助于纤维性疾病.
-葡萄糖共运输体2 (SGLT2) 抑制剂已经显示出抗衰老作用.
腹膜纤维化是腹膜透析 (PD) 的一个并发症.

研究的目的:

研究SGLT2抑制剂empagliflozin对EMT的抗衰发作用.
评估empagliflozin对腹膜纤维化模型的影响.

主要方法:

试验室内:用葡萄糖和empagliflozin治疗人类腹间皮细胞 (HPMCs).
在体内:雄性小鼠接受了腹膜透析 (PD),有或没有empagliflozin治疗.
评估了衰老标志物 (p53,p21,p16),EMT标志物,活性氧物种,DNA损伤和腹腔组织形态.

主要成果:

葡萄糖诱导HPMC中的EMT,增加衰老和氧化应激,而empagliflozin减弱了这些.
恩帕格利弗洛辛在HPMC中降低了葡萄糖诱导的EMT和衰老标志物.
在PD小鼠中,empagliflozin降低了腹膜厚度,原沉积和衰老/EMT标记.

结论:

恩帕格利弗洛辛通过减少衰老,有效地抑制HPMC中葡萄糖诱导的EMT.
在PD的小鼠模型中,empagliflozin治疗改善了腹纤维化.
恩帕格利弗洛辛 (empagliflozin) 显示出作为一种新型治疗剂,用于预防或治疗腹膜纤维化.

关键词:

纤维化纤维化腹膜透析是指腹膜透析.衰老是一种老化.-葡萄糖共运输体 2 2

更多相关视频

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

Published on: April 28, 2022

相关概念视频

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...

Peritoneal Dialysis III: Nursing Management

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...